Pancreatic cancer screening: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
m Bot: Removing from Primary care |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine screening for pancreatic cancer due to the lack of mortality benefit. In high-risk individuals, with familial pancreatic cancer or in those with genetic syndromes predisposing to pancreatic cancer, screening is suggested. In high- risk groups, screening by [[endoscopic ultrasound]] ([[Endoscopic ultrasound|EUS]]), [[magnetic resonance imaging]] ([[Magnetic resonance imaging|MRI]]) and [[magnetic resonance cholangiopancreatography]] ([[Magnetic resonance cholangiopancreatography|MRCP]]) are recommended. | In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine [[Screening (medicine)|screening]] for [[pancreatic cancer]] due to the lack of [[Mortality rate|mortality]] benefit. In high-risk individuals, with familial [[pancreatic cancer]] or in those with [[Genetic|genetic syndromes]] predisposing to [[pancreatic cancer]], [[Screening (medicine)|screening]] is suggested. In high- risk groups, [[Screening (medicine)|screening]] by [[endoscopic ultrasound]] ([[Endoscopic ultrasound|EUS]]), [[magnetic resonance imaging]] ([[Magnetic resonance imaging|MRI]]) and [[magnetic resonance cholangiopancreatography]] ([[Magnetic resonance cholangiopancreatography|MRCP]]) are recommended. | ||
==Screening== | ==Screening== | ||
*In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine screening for pancreatic cancer due to the lack of mortality benefit. | *In asymptomatic adults who are at average risk, the ''U.S.P.S.T.F'' recommends against routine screening for [[pancreatic cancer]] due to the lack of mortality benefit. | ||
*In high-risk individuals, with familial pancreatic cancer or in those with genetic syndromes predisposing to pancreatic cancer, screening is suggested. In high- risk groups, screening by [[endoscopic ultrasound]] ([[Endoscopic ultrasound|EUS]]), [[magnetic resonance imaging]] ([[Magnetic resonance imaging|MRI]]) and [[magnetic resonance cholangiopancreatography]] ([[Magnetic resonance cholangiopancreatography|MRCP]]) are recommended.<ref name="pmid22895395">{{cite journal| author=Poruk KE, Firpo MA, Adler DG, Mulvihill SJ| title=Screening for pancreatic cancer: why, how, and who? | journal=Ann Surg | year= 2013 | volume= 257 | issue= 1 | pages= 17-26 | pmid=22895395 | doi=10.1097/SLA.0b013e31825ffbfb | pmc=4113008 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22895395 }} </ref><ref name="pmid21960811">{{cite journal| author=Greer JB, Brand RE| title=Screening for pancreatic cancer: current evidence and future directions. | journal=Gastroenterol Hepatol (N Y) | year= 2007 | volume= 3 | issue= 12 | pages= 929-38 | pmid=21960811 | doi= | pmc=3104195 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21960811 }} </ref> | *In high-risk individuals, with familial [[pancreatic cancer]] or in those with genetic syndromes predisposing to [[Pancreatic cancer|pancreatic cancer,]] [[Screening (medicine)|screening]] is suggested. In high- risk groups, screening by [[endoscopic ultrasound]] ([[Endoscopic ultrasound|EUS]]), [[magnetic resonance imaging]] ([[Magnetic resonance imaging|MRI]]) and [[magnetic resonance cholangiopancreatography]] ([[Magnetic resonance cholangiopancreatography|MRCP]]) are recommended.<ref name="pmid22895395">{{cite journal| author=Poruk KE, Firpo MA, Adler DG, Mulvihill SJ| title=Screening for pancreatic cancer: why, how, and who? | journal=Ann Surg | year= 2013 | volume= 257 | issue= 1 | pages= 17-26 | pmid=22895395 | doi=10.1097/SLA.0b013e31825ffbfb | pmc=4113008 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22895395 }} </ref><ref name="pmid21960811">{{cite journal| author=Greer JB, Brand RE| title=Screening for pancreatic cancer: current evidence and future directions. | journal=Gastroenterol Hepatol (N Y) | year= 2007 | volume= 3 | issue= 12 | pages= 929-38 | pmid=21960811 | doi= | pmc=3104195 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21960811 }} </ref> | ||
*Screening is recommended in individuals with the following conditions who are at an increased risk of pancreatic cancer:<ref name="pmid26320426">{{cite journal| author=Goral V| title=Pancreatic Cancer: Pathogenesis and Diagnosis. | journal=Asian Pac J Cancer Prev | year= 2015 | volume= 16 | issue= 14 | pages= 5619-24 | pmid=26320426 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26320426 }} </ref> | *[[Screening (medicine)|Screening]] is recommended in individuals with the following conditions who are at an increased risk of [[pancreatic cancer]]:<ref name="pmid26320426">{{cite journal| author=Goral V| title=Pancreatic Cancer: Pathogenesis and Diagnosis. | journal=Asian Pac J Cancer Prev | year= 2015 | volume= 16 | issue= 14 | pages= 5619-24 | pmid=26320426 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26320426 }} </ref> | ||
**Hereditary pancreatitis | **[[Hereditary pancreatitis]] | ||
**Familial pancreatic cancer | **[[Familial]] [[pancreatic cancer]] | ||
**Peutz-Jeghers disease | **[[Peutz-Jeghers syndrome|Peutz-Jeghers disease]] | ||
**Familial atypical mole melanoma syndrome (FAMMM) | **Familial atypical mole melanoma syndrome (FAMMM) | ||
**Cystic fibrosis of pancreas | **[[Cystic fibrosis]] of pancreas | ||
**Familial cancer syndromes such as: | **Familial [[cancer]] syndromes such as: | ||
***Lynch syndrome | ***[[Lynch syndrome]] | ||
***Familial adenomatous polyposis (FAP) | ***[[Familial adenomatous polyposis]] ([[FAP]]) | ||
*** | ***[[Von Hippel-Lindau disease|Von Hippel-Lindau syndrome]] | ||
***Multiple endocrine neoplasia type 1 | ***[[Multiple endocrine neoplasia type 1]] | ||
***Hereditary breast and ovarian cancer-BRCA1 and BRCA2 mutations | ***Hereditary [[Breast cancer|breast]] and [[ovarian cancer]] - [[BRCA1]] and [[BRCA2]] [[Mutation|mutations]] | ||
==References== | ==References== | ||
| Line 29: | Line 29: | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Surgery]] | |||
[[Category:Gastroenterology]] | |||
Latest revision as of 23:33, 29 July 2020
|
Pancreatic cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancreatic cancer screening On the Web |
|
American Roentgen Ray Society Images of Pancreatic cancer screening |
|
Risk calculators and risk factors for Pancreatic cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine screening for pancreatic cancer due to the lack of mortality benefit. In high-risk individuals, with familial pancreatic cancer or in those with genetic syndromes predisposing to pancreatic cancer, screening is suggested. In high- risk groups, screening by endoscopic ultrasound (EUS), magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) are recommended.
Screening
- In asymptomatic adults who are at average risk, the U.S.P.S.T.F recommends against routine screening for pancreatic cancer due to the lack of mortality benefit.
- In high-risk individuals, with familial pancreatic cancer or in those with genetic syndromes predisposing to pancreatic cancer, screening is suggested. In high- risk groups, screening by endoscopic ultrasound (EUS), magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) are recommended.[1][2]
- Screening is recommended in individuals with the following conditions who are at an increased risk of pancreatic cancer:[3]
- Hereditary pancreatitis
- Familial pancreatic cancer
- Peutz-Jeghers disease
- Familial atypical mole melanoma syndrome (FAMMM)
- Cystic fibrosis of pancreas
- Familial cancer syndromes such as:
References
- ↑ Poruk KE, Firpo MA, Adler DG, Mulvihill SJ (2013). "Screening for pancreatic cancer: why, how, and who?". Ann Surg. 257 (1): 17–26. doi:10.1097/SLA.0b013e31825ffbfb. PMC 4113008. PMID 22895395.
- ↑ Greer JB, Brand RE (2007). "Screening for pancreatic cancer: current evidence and future directions". Gastroenterol Hepatol (N Y). 3 (12): 929–38. PMC 3104195. PMID 21960811.
- ↑ Goral V (2015). "Pancreatic Cancer: Pathogenesis and Diagnosis". Asian Pac J Cancer Prev. 16 (14): 5619–24. PMID 26320426.